Pathology: laHNSCC - 1st line (L1); mHNSCC - L1 - all population; mHNSCC - L1 - PDL1 positive; mHNSCC - L2 - all population; mHNSCC - L2 - PDL1 negative; mHNSCC - L2 - PDL1 positive;
| laHNSCC - 1st line (L1) | mHNSCC - L1 - all population | mHNSCC - L1 - PDL1 positive | mHNSCC - L2 - all population | mHNSCC - L2 - PDL1 negative | mHNSCC - L2 - PDL1 positive | ||||||||||
| JAVELIN Head and Neck 100, 2021 | KEYNOTE-048 (P vs C ; all population), 2019 | KEYNOTE-048 (PC vs C ; all population), 2019 | KEYNOTE-048 (P vs C ; CPS > 20), 2019 | KEYNOTE-048 (P vs C ; CPS > 1), 2019 | KEYNOTE-048 (PC vs C ; CPS > 20), 2019 | KEYNOTE-048 (PC vs C ; CPS > 1), 2019 | EAGLE (D vs ICC), 2019 | EAGLE (DT vs ICC), 2019 | CheckMate 141, 2016 | KEYNOTE-040 (all population), 2018 | CONDOR (DT vs D ; PDL1 TC<25%), 2019 | CONDOR (DT vs T ; PDL1 TC<25%), 2019 | KEYNOTE-040 (CPS >1), 2018 | ||
| pembrolizumab alone | 5 | T1 | T1 | T1 | T1 | T1 | |||||||||
| pembrolizumab plus 5FU plus platin | 3 | T1 | T1 | T1 | |||||||||||
| durvalumab plus tremelimumab | 3 | T1 | T1 | T1 | |||||||||||
| avelumab alone | 1 | T1 | |||||||||||||
| durvalumab alone | 1 | T1 | T0 | ||||||||||||
| nivolumab alone | 1 | T1 | |||||||||||||
| placebo | 0 | T0 | |||||||||||||
| cetuximab plus platin plus 5FU | 0 | T0 | T0 | T0 | T0 | T0 | T0 | ||||||||
| tremelimumab | 0 | T0 | |||||||||||||
| Standard of Care (SoC) | 0 | T0 | T0 | T0 | T0 | T0 | |||||||||